Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-γ ligand rosiglitazone
BA Neuschwander-Tetri, EM Brunt, KR Wehmeier… - Hepatology, 2003 - Elsevier
Insulin resistance (IR) commonly is associated with nonalcoholic steatohepatitis (NASH). To
establish whether IR causes NASH, this study was undertaken to determine if improving IR
would improve the histologic features that define NASH. Thirty adults with prior biopsy
evidence of NASH were enrolled to receive rosiglitazone, 4 mg twice daily for 48 weeks. All
patients were overweight (body mass index [BMI]> 25 kg/m2) and 23% were severely obese
(BMI> 35 kg/m2); 50% had impaired glucose tolerance or diabetes. Liver biopsy specimens …
establish whether IR causes NASH, this study was undertaken to determine if improving IR
would improve the histologic features that define NASH. Thirty adults with prior biopsy
evidence of NASH were enrolled to receive rosiglitazone, 4 mg twice daily for 48 weeks. All
patients were overweight (body mass index [BMI]> 25 kg/m2) and 23% were severely obese
(BMI> 35 kg/m2); 50% had impaired glucose tolerance or diabetes. Liver biopsy specimens …